These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 12678725)

  • 1. Targeting human telomerase in cancer therapy.
    Huard S; Autexier C
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):577-87. PubMed ID: 12678725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to inhibit telomerase activity for cancer therapy.
    Kyo S; Inoue M
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase: a target for cancer therapeutics.
    Shay JW; Wright WE
    Cancer Cell; 2002 Oct; 2(4):257-65. PubMed ID: 12398889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomeres and telomerase: Pharmacological targets for new anticancer strategies?
    Pendino F; Tarkanyi I; Dudognon C; Hillion J; Lanotte M; Aradi J; Ségal-Bendirdjian E
    Curr Cancer Drug Targets; 2006 Mar; 6(2):147-80. PubMed ID: 16529544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
    Rankin AM; Faller DV; Spanjaard RA
    Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligonucleotides and G-quadruplex stabilizers: targeting telomeres and telomerase in cancer therapy.
    Crees Z; Girard J; Rios Z; Botting GM; Harrington K; Shearrow C; Wojdyla L; Stone AL; Uppada SB; Devito JT; Puri N
    Curr Pharm Des; 2014; 20(41):6422-37. PubMed ID: 24975605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting human telomerase by antisense oligonucleotides and ribozymes.
    Folini M; Pennati M; Zaffaroni N
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):605-12. PubMed ID: 12678727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomeres and telomerase as targets for anticancer drug development.
    Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC
    Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligonucleotide inhibitors of telomerase: prospects for anticancer therapy and diagnostics.
    Zvereva MI; Zatsepin TS; Azhibek DM; Shubernetskaya OS; Shpanchenko OV; Dontsova OA
    Biochemistry (Mosc); 2015 Mar; 80(3):251-9. PubMed ID: 25761680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Telomeres and telomerase as targeted therapies in cancer treatment].
    Souiden Y; Bouraoui A; Chaieb K; Mahdouani K
    Bull Cancer; 2010 Sep; 97(9):1087-104. PubMed ID: 20663741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting telomeres and telomerase.
    De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
    Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase inhibitors: a patent review (2010-2015).
    Man RJ; Chen LW; Zhu HL
    Expert Opin Ther Pat; 2016 Jun; 26(6):679-88. PubMed ID: 27104627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
    Herbert BS; Pongracz K; Shay JW; Gryaznov SM
    Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of telomerase inhibitors for the treatment of cancer.
    Cairns D; Anderson RJ; Perry PJ; Jenkins TC
    Curr Pharm Des; 2002; 8(27):2491-504. PubMed ID: 12369943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer therapy targeting telomeres and telomerase : current status.
    Parkinson EK; Minty F
    BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agents that target telomerase and telomeres.
    Raymond E; Sun D; Chen SF; Windle B; Von Hoff DD
    Curr Opin Biotechnol; 1996 Dec; 7(6):583-91. PubMed ID: 8939642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death.
    Herbert B; Pitts AE; Baker SI; Hamilton SE; Wright WE; Shay JW; Corey DR
    Proc Natl Acad Sci U S A; 1999 Dec; 96(25):14276-81. PubMed ID: 10588696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomere biology of pediatric cancer.
    Tabori U; Dome JS
    Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomere maintenance mechanisms as a target for drug development.
    Bearss DJ; Hurley LH; Von Hoff DD
    Oncogene; 2000 Dec; 19(56):6632-41. PubMed ID: 11426649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.